OneMedNet (NASDAQ:ONMD) shares are trading lower on Tuesday, possibly on continued weakness after the stock rallied on Friday following a recent announcement about the next phase of its real-world data (RWD) platform.
On Monday, the stock closed 26.55% lower.
ONMD’s Growth Strategy Through RWD Platform
The company is actively converting customer evaluations into commercial subscriptions, which are expected to drive predictable growth and millions in incremental annual recurring revenue (ARR).
CEO Aaron Green noted that customer feedback has reinforced the platform's performance, speed, and depth of discovery, validating their strategy of combining AI-driven search with scalable data feeds.
OneMedNet has integrated over 2,130 healthcare sites into its iRWD platform powered by Palantir Technologies Inc. (NYSE:PLTR).
The strategic move is set to accelerate the adoption of its platform among life sciences and AI health innovators, providing customers with near-real-time access to integrated clinical and longitudinal datasets.
"Customer feedback has reinforced the platform's performance, speed, and depth of discovery," said CEO Aaron Green. "We believe this traction validates our strategy of combining conversational AI-driven search with scalable, prospective data feeds, strengthening customer confidence as we expand subscriptions and deliver fast, intuitive value for Real-World evidence generation."
Benefits for Investors
Commercial launch advances OneMedNet’s high-margin recurring revenue model. Evaluation conversions to multi-year subscriptions are happening now, which can drive predictable growth and millions in incremental annual recurring revenue.
Network expansion should boost deal sizes and penetration in life sciences/AI/research, fueling sustained bookings.
Benefits for Customers
Life sciences teams, health systems, and researchers are expected to gain near real-time access to comprehensive regulatory-grade multimodal real-world data; an AI-powered search for nuanced insights across clinical and imaging, longitudinal data; faster cohort building/feasibility (weeks to minutes); and tools enhancing real-world evidence study design, submissions, and evidence generation—accelerating innovation and reducing trial risks.
ONMD Price Action: OneMedNet shares were down 11.51% at $0.67 during premarket trading on Tuesday, according to Benzinga Pro data.
Image: Shutterstock
